BRPI0719559A2 - Uso de inibidores de iap para o tratamento de leucemia mieloide aguda - Google Patents

Uso de inibidores de iap para o tratamento de leucemia mieloide aguda

Info

Publication number
BRPI0719559A2
BRPI0719559A2 BRPI0719559-1A2A BRPI0719559A BRPI0719559A2 BR PI0719559 A2 BRPI0719559 A2 BR PI0719559A2 BR PI0719559 A BRPI0719559 A BR PI0719559A BR PI0719559 A2 BRPI0719559 A2 BR PI0719559A2
Authority
BR
Brazil
Prior art keywords
treatment
myeloid leukemia
acute myeloid
iap inhibitors
iap
Prior art date
Application number
BRPI0719559-1A2A
Other languages
English (en)
Inventor
Leigh Zawel
Yao Yao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0719559A2 publication Critical patent/BRPI0719559A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0719559-1A2A 2006-11-28 2007-11-26 Uso de inibidores de iap para o tratamento de leucemia mieloide aguda BRPI0719559A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86745006P 2006-11-28 2006-11-28
PCT/US2007/085486 WO2008085610A1 (en) 2006-11-28 2007-11-26 Use of iap inhibitors for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BRPI0719559A2 true BRPI0719559A2 (pt) 2014-01-21

Family

ID=39342685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719559-1A2A BRPI0719559A2 (pt) 2006-11-28 2007-11-26 Uso de inibidores de iap para o tratamento de leucemia mieloide aguda

Country Status (11)

Country Link
US (1) US20100076013A1 (pt)
EP (1) EP2089027A1 (pt)
JP (1) JP2010511057A (pt)
KR (1) KR20090083412A (pt)
CN (1) CN101541325A (pt)
AU (1) AU2007342225A1 (pt)
BR (1) BRPI0719559A2 (pt)
CA (1) CA2670270A1 (pt)
EA (1) EA200900691A1 (pt)
MX (1) MX2009005551A (pt)
WO (1) WO2008085610A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
RU2418807C2 (ru) 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
WO2011035083A1 (en) * 2009-09-18 2011-03-24 Novartis Ag Biomarkers for iap inhibitor compounds
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238650A1 (en) * 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
EP2606933A3 (en) * 2005-12-20 2014-10-15 Novartis AG Combination of an IAP-inhibitor and a taxane
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
US20100076013A1 (en) 2010-03-25
EA200900691A1 (ru) 2009-12-30
JP2010511057A (ja) 2010-04-08
MX2009005551A (es) 2009-06-08
EP2089027A1 (en) 2009-08-19
KR20090083412A (ko) 2009-08-03
CN101541325A (zh) 2009-09-23
AU2007342225A1 (en) 2008-07-17
WO2008085610A1 (en) 2008-07-17
CA2670270A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0921482A2 (pt) tratamento de leucemia linfoblástica aguda
BRPI0717411A2 (pt) Uso de inibidores de iap
DK1851200T3 (da) Dimere iap-inhibitorer
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
EP1971595A4 (en) CETP INHIBITORS
EP1973889A4 (en) Cetp inhibitors
LT2478907T (lt) Kompozicijos vėžiui gydyti
IL183938A0 (en) Amino - imidazolones for the inhibition of ?? - becretase
DE602007001549D1 (de) Substrathaltevorrichtung
IL196470A0 (en) Antagonist antibody against epha2 for the treatment of cancer
EP4125244C0 (en) HASH BASED MULTIHOSTING
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
BRPI1016182A2 (pt) método para o tratamento da leucemia mieloide aguda
FI20055661A0 (fi) Prosessi tyydyttyneen hiilivetykomponentin valmistamiseksi
NO20076008L (no) Holdeinnretning
BRPI0618203A2 (pt) aparelho de revestimento
BRPI0911515A2 (pt) dispositivos formadores rotatórios e métodos para o uso de tais dispositivos.
EP1951053A4 (en) CETP INHIBITORS
EP1910272A4 (en) Renin Inhibitors
DE112005003540A5 (de) Zahnradhonmaschine
DE502007001783D1 (de) Bauteilhalterung
EP2043933A4 (en) FOOD MECHANISM FOIL SHEET

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired